These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38134199)

  • 1. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
    Ye Z; Bonam SR; McKay LGA; Plante JA; Walker J; Zhao Y; Huang C; Chen J; Xu C; Li Y; Liu L; Harmon J; Gao S; Song D; Zhang Z; Plante KS; Griffiths A; Chen J; Hu H; Xu Q
    Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2311752120. PubMed ID: 38134199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants.
    Mahalingam G; Rachamalla HK; Arjunan P; Karuppusamy KV; Periyasami Y; Mohan A; Subramaniyam K; M S; Rajendran V; Moorthy M; Varghese GM; Mohankumar KM; Thangavel S; Srivastava A; Marepally S
    Mol Ther; 2024 May; 32(5):1284-1297. PubMed ID: 38414245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
    Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
    J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models.
    Hajnik RL; Plante JA; Liang Y; Alameh MG; Tang J; Bonam SR; Zhong C; Adam A; Scharton D; Rafael GH; Liu Y; Hazell NC; Sun J; Soong L; Shi PY; Wang T; Walker DH; Sun J; Weissman D; Weaver SC; Plante KS; Hu H
    Sci Transl Med; 2022 Sep; 14(662):eabq1945. PubMed ID: 36103514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models.
    Lelis F; Byk LA; Pustylnikov S; Nguyen V; Nguyen B; Nitz M; Tarte P; Tungare K; Li J; Manna S; Maiti S; Mehta DH; Sekar N; Posadas DM; Dhamankar H; Hughes JA; Aulisa L; Khan A; Melo MB; Dey AK
    Sci Rep; 2023 Dec; 13(1):21172. PubMed ID: 38040905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
    Prakash S; Dhanushkodi NR; Singer M; Quadiri A; Zayou L; Vahed H; Coulon PG; Ibraim IC; Tafoya C; Hitchcock L; Landucci G; Forthal DN; El Babsiri A; Tifrea DF; Figueroa CJ; Nesburn AB; Kuppermann BD; Gil D; Jones TM; Ulmer JB; BenMohamed L
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19.
    Kackos CM; Surman SL; Jones BG; Sealy RE; Jeevan T; Davitt CJH; Pustylnikov S; Darling TL; Boon ACM; Hurwitz JL; Samsa MM; Webby RJ
    Microbiol Spectr; 2023 Feb; 11(1):e0424022. PubMed ID: 36695597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern.
    Kumari M; Su SC; Liang KH; Lin HT; Lu YF; Chen KC; Chen WY; Wu HC
    J Biomed Sci; 2023 Jun; 30(1):46. PubMed ID: 37380988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
    Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
    Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model.
    Zhang Y; Zhang J; Li D; Mao Q; Li X; Liang Z; He Q
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models.
    Guimaraes LC; Costa PAC; Scalzo Júnior SRA; Ferreira HAS; Braga ACS; de Oliveira LC; Figueiredo MM; Shepherd S; Hamilton A; Queiroz-Junior CM; da Silva WN; da Silva NJA; Rodrigues Alves MT; Santos AK; de Faria KKS; Marim FM; Fukumasu H; Birbrair A; Teixeira-Carvalho A; de Aguiar RS; Mitchell MJ; Teixeira MM; Vasconcelos Costa V; Frezard F; Guimaraes PPG
    Nat Commun; 2024 Jan; 15(1):590. PubMed ID: 38238326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster.
    Lloren KKS; Jawalagatti V; Hewawaduge C; Chandran S; Park JY; Lee JH
    Microbes Infect; 2023 Jun; 25(5):105101. PubMed ID: 36657635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.
    Hawman DW; Meade-White K; Clancy C; Archer J; Hinkley T; Leventhal SS; Rao D; Stamper A; Lewis M; Rosenke R; Krieger K; Randall S; Khandhar AP; Hao L; Hsiang TY; Greninger AL; Gale M; Berglund P; Fuller DH; Rosenke K; Feldmann H; Erasmus JH
    EBioMedicine; 2022 Sep; 83():104196. PubMed ID: 35932641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.